Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Tarsus Pharmaceuticals, Inc. TARS
$16.58
-$0.47 (-2.81%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
429388866.00000000
-
week52high
19.66
-
week52low
11.33
-
Revenue
25816000
-
P/E TTM
-6
-
Beta
0.62833300
-
EPS
-2.57000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:05
Описание компании
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Barclays | Overweight | 01 авг 2022 г. | |
| HC Wainwright & Co. | Buy | 21 дек 2021 г. | |
| Oppenheimer | Outperform | 23 ноя 2021 г. | |
| Raymond James | Strong Buy | Strong Buy | 08 окт 2021 г. |
| Raymond James | Strong Buy | Strong Buy | 29 июн 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Azamian Bobak R. | D | 1111106 | 4856 | 23 янв 2023 г. |
| Azamian Bobak R. | D | 1116373 | 240 | 20 янв 2023 г. |
| Greenstein Leonard M. | D | 39289 | 5000 | 19 янв 2023 г. |
| Azamian Bobak R. | D | 1116613 | 8000 | 18 янв 2023 г. |
| Azamian Bobak R. | D | 1124613 | 3904 | 11 янв 2023 г. |
| Azamian Bobak R. | D | 1128517 | 905 | 10 янв 2023 г. |
| Azamian Bobak R. | D | 1129422 | 729 | 09 янв 2023 г. |
| Azamian Bobak R. | D | 1129740 | 411 | 06 янв 2023 г. |
| Azamian Bobak R. | D | 1130151 | 8000 | 21 дек 2022 г. |
| Azamian Bobak R. | D | 1138151 | 535 | 16 дек 2022 г. |
Новостная лента
Tarsus Pharma: Excellent Data, Nice Execution, Unclear Market Potential
Seeking Alpha
24 янв 2023 г. в 14:02
Tarsus ran two pivotal trials in an eye indication. Data was excellent and shows that TP-03 will help patients.
Strength Seen in Tarsus Pharmaceuticals, Inc. (TARS): Can Its 5.0% Jump Turn into More Strength?
Zacks Investment Research
24 янв 2023 г. в 06:01
Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
GlobeNewsWire
25 окт 2022 г. в 08:30
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis
Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings
GlobeNewsWire
27 сент 2022 г. в 12:00
Positive d ata to be presented at WCC VIII and AAO 2022 conferences in Chicago
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research
11 авг 2022 г. в 18:49
Tarsus Pharmaceuticals, Inc. (TARS) delivered earnings and revenue surprises of 63.08% and 8.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?